Our team has been diligently searching for the next potential breakout CSE company to add to our watchlist, and this hidden gem shows limitless potential.
Meet LOVE PHARMA (CSE:LUV)
LOVE Pharma specializes in mental health and sexual wellness by licensing and distributing psychedelic and hemp-infused products.
Lets take a look at the industry …
The alternative wellness industry is carving a niche within the global mental health market, which as a whole was valued at US $381.98 billion in 2020, and is estimated to grow to US $527.44 billion by 2030. (1)
But this company is rapidly expanding within a niche sector within the market…
Data Bridge Market Research analysis suggests that the pharmaceutical psychedelic market is growing with a CAGR of 13.3% in the forecast period of 2022 to 2029 and is expected to reach over USD 8MM by 2029 from USD 2.9 MM in 2021. (2)
That’s a good-sized slice of a very substantial pie.
As regulations evolve with respect to alternative medicinal practices, Love Pharma is firmly staking their claim at the ground floor. This industry is unequivocally blowing up at an astounding rate, and having been listed on the CSE since September 2021, a strategic foothold has been firmly planted.
Let’s start with a brief recap of the company, though.
With a focus on the global sexual Health and Wellness markets, Love Pharma Inc. (CSE: LUV) (FSE: G1Q0) was founded in 2020, with the intention to bring innovative sexual health-and-wellness products to market. The company holds exclusive licenses to produce, market, package, sell and distribute patent-protected therapeutic and pharmaceutical products throughout Europe, the United Kingdom, and North America.
The company’s growth and development plan took a major leap forward this month, with the announcement that Love Pharma is establishing a strategic alliance with Starton Therapeutics (Starton), a leading clinical-stage biotechnology company in the United States. Most notably, Starton is focused on transforming standard of care therapies with proprietary continuous delivery technology, allowing individuals undergoing cancer treatment to receive continuous treatment to live better, longer.
This company has only been listed since September of 2021, and they’ve gained attention quickly.
All signs point to an opportunity with limitless potential in a market space that is growing rapidly.
- AT THE TIME OF THIS WRITING – SEPT 21, 2022 – The company has just announced the launce of the Love Pharma online shop, a fully integrated e-commerce platform featuring its proprietary product
- Love Pharma (CSE:LUV) Acquired the rights to a patent-pending psilocybin strip, which utilizes already-existing novel technology implemented for the mucoadhesive CBD Strip.
- Significant near and mid-term growth catalysts – 7.2% CAGR over the next 10 years (nutraceuticals)(3)
- Investing in sustainable, long-term revenue with proven products, technologies, and established sales performance
- Retail ready products for cross-channel promotion to include DTC, brick & mortar, MLM, closed networks, white labeling, and others
- 6 exclusively licensed technologies
- Experienced, long-term, drug and nutraceutical team
- Domestic and international expansion
- Love Pharma (CSE:LUV) became a player to watch right out of the gate with the release of their fertility line, strategically launched in staggered phases so as not to dilute each products impact.
No one likes to talk about infertility, especially young healthy foks. This company nailed the marketing strategy within a giant, but under-discussed market – 75% of unexplained infertility cases are related to lubrication issues, insufficiency, or ingredients that are detrimental to sperm. (4)
The United States sexual wellness market is expected to reach US$15.9 billion by 2027, (5)
But they were not done.
We mentioned the Global Mental Health Market earlier, and this is where things start to heat up….
LUV Pharma the Company paired with the creator of a muco-adhesive sublingual strip to develop it for use as a psilocybin delivery system.
As psilocybin has gained increased legitimacy in the mental healthcare field, and this school of thought is growing rapidly following a 2018 “breakthrough” designation by the FDA, allowing for the fast-tracking of drug-trials. (6)
A recent Phase II study at Imperial College London found psilocybin performed just as well as Lexapro™-a widely used antidepressant-in easing the symptoms of major depression; and outperformed the prescription medication on a range of secondary measures.
Remember that 381.98 billion Mental Health Care market in the US alone? Thsi company is on the ground floor.
When evaluating public companies within this industry, the management team is a salient factor.
Love Pharma (CSE:LUV) boasts an incredibly well rounded team. The directors and management are comprised of individuals with an extensive arsenal of skills.
- Specialists in corporate development, equity, private equity, venture capital financing, private placements and investor relations
- CFO with prior experience in the cannabinoid industry
- Prior CEO of GLenbriar with extensive strategic planning experience
- Financial specialist with trans border expertise
- Consumer goods specialist with a focus on OTC drug and nutraceutical development including regulatory clinical research.
This leadership team is advantateously positioned to address regulatory, sales, and licensing directives skillfully, and with precise tactical knowledge of the industry.
Our team is excited to see what Love Pharma (CSE:LUV) is planning next, make sure this company is the top of your watch list.
Remember – the fastest way to gain insight on potential rising stars on the CSE is through SMS.
Be the FIRST TO KNOW and the FIRST TO PROFIT
TEXT ALERTS to 877-324-4747
Chat soon, The Team at CA Stocks
© 2022 CAStocks (herein referred to as “CAS”) Powered By GloBull Media LLC.
CAStocks Newsletter: CAStock’s Newsletter is published as a copyright publication of castocks.com
No Guarantee as to Content: Although CAS attempts to research thoroughly and present information based on sources we believe to be reliable, there are no guarantees as to the accuracy or completeness of the information contained herein. Any statements expressed are subject to change without notice. The information within this email may contain errors and you should not make any investment decisions based on what you have read herein or read/seen in any CAS websites, newsletters, emails, social media, text messages, push notifications, videos and/or other publications. CAS, its associates, authors, and affiliates are not responsible for errors or omissions. By accessing the site and receiving this email, you accept and agree to be bound by and comply with the terms and conditions as set out herein. If you do not accept and agree to the terms you should not use the CAStocks sites or accept this email.
CAStock’s electronic media, including websites, newsletters, emails, social media, text messages, push notifications, videos and all other CAS published materials are for Canadian residents only.
Conduct your own due diligence: The author’s views and opinions regarding the companies featured in report(s) are his/her own views and are based on information that he/she has researched independently and has received, which the author assumes to be reliable. You should never base any buying/selling/trading decisions off of our emails, newsletters, websites, social media, text messages, push notifications and/or videos or any of our published materials. CAS aims to provide information and often stock ideas but are by no means recommendations. The ideas and companies featured are highly speculative and you could lose your entire investment – consult a licensed financial advisor if you are considering investing in any of the featured companies. Subscribers/readers are encouraged to conduct their own research and due diligence. The companies mentioned are high risk and considered penny stocks that contain a high risk of volatility, therefore consult a licensed investment advisor and do your own due diligence. Never base any investment decision on information contained from our emails, newsletters, websites, social media, text messages, push notifications, videos or any of our published materials.
CAS has a $5,000.00 advertising production budget agreement over 30 business days with the company Love PHarma (CSE:LUV) in an effort to build industry and investor awareness. Any funds leftover after expenses for research, overhead, advertising, and public relations related to Love Pharma will be considered profit. Entities related to CAS. may hold shares in (CSE:LUV) nd are likely to sell those shares. Any such sales of (CSE:LUV) stock will affect the value of your shares (negatively). This should be considered a direct conflict of interest. Please review all investment decisions with a licensed investment advisor. This report is a commercial advertisement and is for general information purposes only. Investorscene.com is engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on this site or emails unless you can afford to lose your entire investment.
No Recommendation to Purchase or Sell Securities: CAS is not a registered broker-dealer, investment advisor, financial analyst, stock picker, investment banker or other investment professional. IS is intended for informational, educational, research and entertainment purposes only. It is not to be considered as investment advice. No statement or expression of any opinions contained in this email/report constitutes an offer to buy or sell the shares of the companies mentioned herein.
Links: CAS and/or CAS’’s publications may contain links to related websites for stock quotes, charts, etc. CAS is not responsible for the content of or the privacy practices of these sites. Information contained herein was extracted from public filings, profiled company websites, and other publicly available sources deemed reliable. Information in this report was taken on or before writing and dissemination and may not be updated. Do you own due diligence as information and events can and do change. Published reports may reference company websites or link to company websites and you agree that CAS is not responsible for the content and accuracy of any such information or website company
Release of Liability: By reading/viewing materials on our websites, emails, newsletters, social media, text messages, push notifications and/or watching videos by CAS, you agree to hold CAS, its associates, sponsors, affiliates, and partners harmless and to completely release them from any and all liabilities due to any and all losses, damages, or injuries (financial or otherwise) that may be incurred.
Forward-Looking Statements: Except for statements of historical fact, certain information contained herein constitutes forward-looking statements. Forward-looking statements are usually identified by the use of certain terminology, including “will”, “believes”, “may”, “expects”, “should”, “seeks”, “anticipates”, “has potential to”, or “intends’ or by discussions of strategy, forward-looking numbers or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which will cause the actual results or achievements to be materially different from any future results or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and include but are not limited to, estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to the effectiveness of the Company’s business model; future operations, products and services; the impact of regulatory initiatives on the Company’s operations; the size of and opportunities related to the market for the Company’s products; general industry and macroeconomic growth rates; expectations related to possible joint and/or strategic ventures and statements regarding future performance. CAS does not take responsibility for the accuracy of forward-looking statements and advises the reader to perform their own due diligence on forward-looking numbers or statements.